Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

326 results
Display

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis

Cheung KS, Mok CH, Mao X, Zhang R, Hung IF, Seto WK, Yuen MF

Background/Aims: Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

Yu JH, Cho SG, Jin YJ, Lee JW

Chronic hepatitis B (CHB) seriously threatens human health. About 820,000 deaths annually are due to related complications such as hepatitis B and hepatocellular carcinoma (HCC). Recently, the use of oral...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
KASL clinical practice guidelines for management of chronic hepatitis B

The Korean Association for the Study of the Liver (KASL)

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Jeong J, Shin JW, Jung SW, Park EJ, Park NH

Background/Aims: Tenofovir alafenamide (TAF) has shown less favorable effect on lipids compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of superb microvascular imaging and shear wave elastography for assessing liver fibrosis in chronic hepatitis B

Tosun M, Uslu H

Purpose: The present study investigated the effectiveness and applicability of superb microvascular imaging (SMI) in determining the degree of liver fibrosis noninvasively in comparison with shear wave elastography (SWE). Methods: Ninety-eight...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Effect of Hepatitis B Virus on COVID-19 Infected Patients: A Nationwide Population-Based Study Using the Health Insurance Review & Assessment Service Database

Choe JW, Jung YK, Yim HJ, Seo GH

Background: Several studies have recently suggested that liver disease and cirrhosis were risk factors for poor outcomes in patients with coronavirus disease 2019 (COVID-19) infections. However, no large data study has...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study

Kang YW, Baek YH, Lee SW, Park SJ, Yoon JS, Yoon KT, Hong Y, Heo NY, Seo KI, Lee SS, Cho HC, Shin JW

Background: The advancement of treatment with direct-acting antiviral (DAA) agents has improved the cure rate of hepatitis C virus (HCV) infection close to 100%. The aim of our study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma

Kwan BS, Kim JH, Park SJ, Choe WH, Kwon SY, Yoo BC

Background/Aims: Chronic hepatitis C (CHC) treatment has dramatically improved since direct-acting antiviral (DAA) therapy was introduced. However, the use of DAA therapy in CHC patients with hepatocellular carcinoma (HCC) remains...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

Tamaki N, Kurosaki M, Loomba R, Izumi N

An accurate evaluation of liver fibrosis is clinically important in chronic liver diseases. Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serum marker for liver fibrosis. In this review,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A dilemma that probably would never resolve

Thanage R, Jain S, Chandnani S, Rathi P

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diagnostic Performance of Serum Asialo α1 -Acid Glycoprotein Levels to Predict Liver Cirrhosis

Lim DH, Kim M, Jun DW, Kwak MJ, Yoon JH, Lee KN, Lee HL, Lee OY, Yoon BC, Choi HS, Kang BK

Background/Aims: To date, studies on various noninvasive techniques have been suggested to evaluate the degree of liver fibrosis. We aimed to investigate the diagnostic performance of se-rum asialo α1-acid glycoprotein...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study

Jeong JY, Jun DW, Park SJ, Sohn JH, Kim SG, Lee SW, Jeong SW, Kim MY, Kim W, Shim JJ, Kim HS, Suk KT, Ahn SB

Background/Aims: We aimed to assess the role of vitamin D supplementation in the response to pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment in patients with chronic hepatitis C (CHC). Methods: Our...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma

Mak LY, Ko KL, To WP, Wong DKH, Seto WK, Fung J, Yuen MF

Serum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Jang BK

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The dilemma of differentiating between acute hepatitisB and chronic hepatitis B with acute exacerbation: Isquantitative serology the answer?

Lall S, Agarwala P, Kumar G, Sharma MK, Gupta E

Background/Aims: Acute exacerbations of chronic hepatitis B (CHB-AEs) are common in endemic areas and are often presumed to be acute hepatitis B (AHB) due to their similarities in clinical and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Should physicians go out of the way to differentiatebetween acute hepatitis B and acute exacerbation ofchronic hepatitis B?

Lee HW

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B vaccination and immunotherapies: an update

Stasi C, Silvestri , Voller F

World Health Organization (WHO) estimates that 257 million people were living with chronic hepatitis B virus (HBV) infection. Highest HBV prevalence was found in the WHO Western Pacific Region (6.2%)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Statin Use on Liver Cancer Mortality Considering Hypercholesterolemia and Obesity in Patients with Non-Cirrhotic Chronic Hepatitis B

Kim GA, Shim JJ, Lee JS, Kim BH, Kim JW, Oh CH, Oh CM, Oh IH, Park SY

Little is known about the benefits of statin use on liver cancer mortality among patients with chronic hepatitis B (CHB) considering hypercholesterolemia and obesity. A nationwide retrospective cohort study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Result Patterns and Characteristics of HBeAg and HBV DNA in Patients with Chronic Hepatitis B

Choi EJ, Kim JH, Han MS

BACKGROUND: Discrepancies in the results between hepatitis B e-antigen (HBeAg) and hepatitis B virus (HBV) DNA levels pose difficulties in the management of chronic hepatitis B (CHB). This study aims...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C

Na SK, Song BC

Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr